PROTOTYPE DRUG: Ranitidine (Zantac)
Nursing Process Focus:
Patients Receiving Ranitidine (Zantac)
|Assessment |Potential Nursing Diagnoses |
|Prior to administration |Injury, Risk for (falls) related to drowsiness secondary to drug |
|Obtain complete health history including allergies, drug history and |therapy |
|possible drug interactions |Nutrition, Risk for Imbalanced: Less than body requirements related to |
|Assess for presence/history gastroesophageal reflux disease, gastric |adverse effects of drug therapy |
|ulcer |Pain, related to gastric irritation secondary to ineffective response |
|Obtain vital signs |to drug therapy |
|Assess liver and kidney function, pregnancy status and complete blood|Knowledge, Deficient related to drug therapy and side effects |
|count. | |
|Planning: Patient Goals and Expected Outcomes |
|The patient will: |
|Remain free of side effects including abdominal pain, heartburn, jaundice, hematemesis, and respiratory difficulty. |
|Demonstrate understanding of risks and benefits of drug therapy. |
|Remain free of physical injury |
|Maintain balanced nutrition, and weight within expected levels |
|Implementation |
|Interventions and (Rationales) |Patient Education/Discharge Planning |
|Monitor serum creatinine, AST, ALT alkaline phosphatase and total |Advise patient to: |
|bilirubin. |Report symptoms of liver dysfunction including jaundice, pruritus, |
| |fatigue |
| |Stop smoking while on drug therapy |
| |Abstain from alcohol while taking this medication, as it may potentiate|
| |drowsiness |
|Monitor for bleeding, bruising, including complete blood count. (Drug|Instruct patient to report signs of unusual bleeding such as petechiae |
|may cause thrombocytopenia.) |or excessive bruising |
|Institute safety procedures to protect the patient who experiences |Advise patient not to drive or operate heavy machinery until the |
|dizziness. |response to drug therapy can be evaluated. |
|Evaluation of Outcome Criteria |
|Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”). |
Nursing Process Focus:
Patients Receiving Omeprazole (Prilosec)
|Assessment |Potential Nursing Diagnoses |
|Prior to administration |Injury, Risk for (fall) related to drowsiness secondary to drug therapy|
|Obtain complete health history including allergies, drug history and |Pain, Risk for related to gastric irritation |
|possible drug interactions |Nutrition, Risk for Imblance: less than body requirements related to |
|Assess for presence/history Gastrointestinal distress, |ineffective response to drug therapy |
|gastrointestinal bleeding | |
|Assess alcohol use, complete blood count, renal function, and stool | |
|for occult blood. | |
|Planning: Patient Goals and Expected Outcomes |
|The patient will: |
|Remain free of signs of side effects including headache, dizziness, diarrhea, abdominal pain, hematuria and rash |
|Demonstrate understanding of the risks and benefits of drug therapy. |
|Implementation |
|Interventions and (Rationales) |Patient Education/Discharge Planning |
|Monitor the smoking and food habits of the patient. (Smoking |Advise patient to: |
|increases stomach acid production.) |Abstain from alcohol use while taking this medication |
| |Refrain from spicy foods, caffeine and smoking which may increase |
| |gastric irritation |
|Monitor elimination pattern. (Drug may cause diarrhea.) |Advise patient to keep a food diary to help correlate symptoms with |
| |foods eaten. |
|Periodically monitor urine for the presence of blood and/or protein. |Instruct patient to report change in urine color to health care |
| |provider. |
|Evaluation of Outcome Criteria |
|Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”). |
Nursing Process Focus:
Patients Receiving Diphenoxylate with Atropine (Lomotil)
|Assessment |Potential Nursing Diagnoses |
|Prior to administration: |Fluid volume, Risk for Imbalance: less than body requirements related |
|Obtain complete health history including allergies, drug history and |to fluid loss secondary to diarrhea |
|possible drug interactions |IMpaired skin integrity, Risk for related to diarrhea stools |
|Assess for presence/history of diarrhea, dehydration, electrolyte |Injury, Risk for (falls) related to drowsiness secondary to drug |
|imbalance |therapy |
|Assess sodium level, chloride level, potassium level, stool culture, |Knowledge, Deficient related to drug action and side effects |
|presence of dehydration, vital signs and EKG. | |
|Planning: Patient Goals and Expected Outcomes |
|The patient will: |
|Demonstrate understanding of instructions necessary for drug therapy. |
|Immediately report persistent diarrhea, constipation, abdominal pain, blood in stool, confusion, dizziness or fever. |
|Implementation |
|Interventions and (Rationales) |Patient Education/Discharge Planning |
|Monitor abdomen for distention and degree and location of abdominal |Advise patient to: |
|pain. (This may be sign of toxic megacolon.) |Record the frequency of stools. Instruct patient to note if any blood |
| |is present. |
| |Report any abdominal pain or abdominal distention to the health care |
| |provider immediately |
|Monitor frequency, volume, characteristics, and consistency of stools.|Instruct patient to: |
| |Report worsening of diarrhea to health care provider |
| |Report occurrence of bloody stools to health care provider |
| |Increase fluid intake and to drink electrolyte enriched fluids. |
|Offer ice, gum or sour candy. May swab lips with a glycerine-based |Advise patient to suck on sour candy or chew gum to relieve sensations |
|emollient. (The medication may cause dry mucous membranes.) |of dry mouth. |
|Initiate safety measures to prevent falls. (The medication may cause |Advise patient to: |
|drowsiness.) |Not drive or operate heavy machinery due to drowsiness. |
| |Abstain from the use of alcohol while using this medication |
|Monitor electrolyte levels. |Advise patient to keep all laboratory appointments. |
|Evaluation of Outcome Criteria |
|Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”). |
Nursing Process Focus:
Patients Receiving Prochlorperazine (Compazine)
|Assessment |Potential Nursing Diagnoses |
|Prior to administration: |Injury, Risk for (fall) related to dizziness secondary to drug |
|Obtain complete health history including allergies, drug history and |therapy |
|possible drug interactions |Fluid volume, Risk for Imbalance: deficit related to ineffective |
|Assess for presence/history severe |response to drug therapy |
|nausea, vomiting |Nutrition, Risk for Imbalanced: less than body requirements related |
|Obtain vital signs |to nausea and vomiting |
|Assess for presence of dehydration, sodium level, chloride level, |Knowledge, Deficient, related to drug therapy and side effects |
|potassium level, and temperature. | |
|Planning: Patient Goals and Expected Outcomes |
|The patient will: |
|Demonstrate understanding of need for drug therapy and will comply with all instruction given |
|Remain free of drug side effects including rash, blurred vision, jaundice, tremor and changes in vision. |
|Maintain adequate fluid balance |
|Maintain adequate nutrition |
|Remain free of physical injury |
|Implementation |
|Interventions and (Rationales) |Patient Education/Discharge Planning |
|Monitor neurological status (Seizure threshold is decreased. May need |Advise patient with a seizure disorder that there is an increased |
|to increase seizure medication.) |risk for seizures with this medication. |
|Monitor intake and output (to evaluate drug effectiveness), |Advise patient: |
| |To report continue nausea and vomiting |
| |That medication may cause urine to appear reddish brown |
|Monitor elimination pattern. (Medication may cause urinary retention.) |Instruct patient to report difficult urination to health care |
| |provider. |
|Institute safety procedures to prevent patient falls or injuries. |Advise patient to avoid driving or operating heavy machinery due to |
| |sedating effects of medication. |
|Monitor changes in skin integrity. (Medication may cause gray–blue |Advise patient: |
|discoloration of skin.) |To protect skin from direct sunlight and to use sunscreen |
| |That medication may cause sun exposed skin to turn gray blue |
|Evaluation of Outcome Criteria |
|Evaluste the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”). |
Nursing Process Focus:
Patients Receiving Sibutramine (Meridia)
|Assessment |Potential Nursing Diagnoses |
|Prior to administration: |Nutrition, Risk for Imbalanced: more than body requirements related to|
|Obtain complete health history including allergies, drug history and |ineffective response to drug therapy |
|possible drug interactions |Tissue perfusion, Risk for Ineffective related to adverse effects of |
|Assess for presence/history obesity, desire to lose weight |drug therapy |
|Assess weight, blood pressure, pulse, EKG, liver function and kidney |Gas exchange, Risk for Impaired related to respiratory difficulty |
|function |secondary to adverse effects of drug therapy |
| |Injury, Risk for (anaphylaxis) related to adverse effects of drug |
| |therapy |
| |Knowledge, Deficient related to drug action and side effects |
|Planning: Patient Goals and Expected Outcomes |
|The patient will: |
|Remain free of adverse reaction to drug including severe headache, fever, muscle aches, tachycardia, rash, nausea, vomiting, profuse sweating, |
|tremor, irritability and respiratory difficulty. |
|Demonstrate weight loss within expected range |
|Maintain adequate tissue perfusion |
|Demonstrate knowledge of drug action and side effects |
|Implementation |
|Interventions and (Rationales) |Patient Education/Discharge Planning |
|Obtain medication history for concurrent use of SSRIs. (Medication may |Instruct patient to immediately report the development of any rash, |
|cause serotonin syndrome.) |fever or difficulty breathing. |
|Monitor weight pattern (to evaluate effectiveness of drug therapy). |Advise patient to: |
| |Keep weight record |
| |Report weight increase to health care provider |
|Monitor intake and output (to evaluate compliance with treatment |Encourage patient to: |
|regimen.) |Remain compliant with prescribed dietary and lifestyle modifications |
| |Take medication as prescribed by the health care provider |
|Monitor liver function, bilirubin, alkaline phosphatase and lipid |Advise patient to keep all laboratory appointments. |
|profile. (There is an increased risk of liver dysfunction.) | |
|Monitor patients with narrow angle glaucoma for increased intraocular |Advise patient to report any vision changes to the health care |
|pressure (Medication may worsen condition.) |provider immediately. |
|Evaluation of Outcome Criteria |
|Evaluate the effectiveness of drug therapy by confirming that patient goals and expected outcomes have been met (see “Planning”). |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- zantac interaction with other medications
- interactions for ranitidine hcl
- ranitidine interactions with other medicines
- ranitidine 300 mg drug interactions
- ranitidine drug interactions
- zantac and eliquis
- what kind of cancer does zantac cause
- side effects of zantac 150 mg tablet
- zantac and cancer
- zantac 150 mg tablets recall
- side effects of zantac 300
- side effects of zantac 150 in women